256 related articles for article (PubMed ID: 30302857)
1. Primary breast diffuse large B-cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure.
Hu S; Song Y; Sun X; Su L; Zhang W; Jia J; Bai O; Yang S; Liang R; Li X; Zhang H; Gao Y; Zhang W; Xiao X; Bao H; Wang N; Ren H; Cen X; Yang S; Zhao Y; Wang Y; Wang Y; Liu A; Wang J; Shi Y; Yuan M; Li Y; He X
Cancer Sci; 2018 Dec; 109(12):3943-3952. PubMed ID: 30302857
[TBL] [Abstract][Full Text] [Related]
2. Primary breast diffuse large B-cell lymphoma in the rituximab era: A retrospective study of the Chinese Southwest Oncology Group.
Weng H; Shrestha PR; Hong H; Chen Z; Yu L; Yao Y; Zhang Z; Zou L; Zhu B; Zhou H; Liu X; Liu Y; Guo H; Huang H; Lin T
Cancer Med; 2023 Dec; 12(23):21188-21198. PubMed ID: 37997571
[TBL] [Abstract][Full Text] [Related]
3. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
4. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era.
Hosein PJ; Maragulia JC; Salzberg MP; Press OW; Habermann TM; Vose JM; Bast M; Advani RH; Tibshirani R; Evens AM; Islam N; Leonard JP; Martin P; Zelenetz AD; Lossos IS
Br J Haematol; 2014 May; 165(3):358-63. PubMed ID: 24467658
[TBL] [Abstract][Full Text] [Related]
5. Role of radiation therapy in primary breast diffuse large B-cell lymphoma in the Rituximab era: a SEER database analysis.
Liu PP; Wang KF; Jin JT; Bi XW; Sun P; Wang Y; Yang H; Li ZM; Jiang WQ; Xia Y
Cancer Med; 2018 May; 7(5):1845-1851. PubMed ID: 29624913
[TBL] [Abstract][Full Text] [Related]
6. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.
Yhim HY; Kim JS; Kang HJ; Kim SJ; Kim WS; Choi CW; Eom HS; Kim JA; Lee JH; Won JH; Shim H; Huh J; Lee DH; Suh C; Kwak JY
Int J Cancer; 2012 Jul; 131(1):235-43. PubMed ID: 21823120
[TBL] [Abstract][Full Text] [Related]
7. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
[TBL] [Abstract][Full Text] [Related]
8. Role of consolidative radiation therapy for patients with mediastinal diffuse large B-cell lymphoma in the rituximab era.
Sert F; Kamer S; Saydam G; Anacak Y
J Cancer Res Ther; 2018; 14(6):1397-1402. PubMed ID: 30488862
[TBL] [Abstract][Full Text] [Related]
9. Reduced radiotherapy clinical benefit for primary Waldeyer's ring diffuse large B-cell lymphoma in the rituximab era.
Guan Q; Hong Y; Hu G; Zhou Q; Li L; Qian Z; Zhou S; Ren X; Qiu L; Wang X; Zhang H
Hematol Oncol; 2021 Oct; 39(4):490-497. PubMed ID: 33908077
[TBL] [Abstract][Full Text] [Related]
10. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era.
Kridel R; Telio D; Villa D; Sehn LH; Gerrie AS; Shenkier T; Klasa R; Slack GW; Tan K; Gascoyne RD; Connors JM; Savage KJ
Br J Haematol; 2017 Jan; 176(2):210-221. PubMed ID: 27739058
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era.
Bobillo S; Joffe E; Lavery JA; Sermer D; Ghione P; Noy A; Caron PC; Hamilton A; Hamlin PA; Horwitz SM; Kumar A; Matasar MJ; Moskowitz A; Owens CN; Palomba ML; Batlevi CL; Straus D; von Keudell G; Zelenetz AD; Yahalom J; Dogan A; Seshan VE; Younes A
Blood; 2021 Jan; 137(1):39-48. PubMed ID: 32730585
[TBL] [Abstract][Full Text] [Related]
12. Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era.
Hunter BD; Herr M; Meacham PJ; Barlaskar F; Evans AG; Burack WR; Liesveld JL; Becker MW; Milner LA; Constine LS; Dhakal S; Barr PM; Friedberg JW; Casulo C
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):145-151. PubMed ID: 27998707
[TBL] [Abstract][Full Text] [Related]
13. Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium.
Deng L; Xu-Monette ZY; Loghavi S; Manyam GC; Xia Y; Visco C; Huh J; Zhang L; Zhai Q; Wang Y; Qiu L; Dybkær K; Chiu A; Perry AM; Zhang S; Tzankov A; Rao H; Abramson J; Sohani AR; Xu M; Hsi ED; Zhu J; Ponzoni M; Wang S; Li L; Zhang M; Ferreri AJ; Parsons BM; Li Y; Piris MA; Medeiros LJ; Young KH
Leukemia; 2016 Feb; 30(2):361-72. PubMed ID: 26308769
[TBL] [Abstract][Full Text] [Related]
14. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
Schmitz N; Zeynalova S; Nickelsen M; Kansara R; Villa D; Sehn LH; Glass B; Scott DW; Gascoyne RD; Connors JM; Ziepert M; Pfreundschuh M; Loeffler M; Savage KJ
J Clin Oncol; 2016 Sep; 34(26):3150-6. PubMed ID: 27382100
[TBL] [Abstract][Full Text] [Related]
15. Intravenous but not intrathecal central nervous system-directed chemotherapy improves survival in patients with testicular diffuse large B-cell lymphoma.
Mannisto S; Vähämurto P; Pollari M; Clausen MR; Jyrkkiö S; Kellokumpu-Lehtinen PL; Kovanen P; Karjalainen-Lindsberg ML; d'Amore F; Leppä S
Eur J Cancer; 2019 Jul; 115():27-36. PubMed ID: 31082690
[TBL] [Abstract][Full Text] [Related]
16. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
[TBL] [Abstract][Full Text] [Related]
17. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab.
Miyazaki K; Yamaguchi M; Suzuki R; Kobayashi Y; Maeshima AM; Niitsu N; Ennishi D; Tamaru JI; Ishizawa K; Kashimura M; Kagami Y; Sunami K; Yamane H; Nishikori M; Kosugi H; Yujiri T; Hyo R; Katayama N; Kinoshita T; Nakamura S
Ann Oncol; 2011 Jul; 22(7):1601-1607. PubMed ID: 21199885
[TBL] [Abstract][Full Text] [Related]
18. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
[TBL] [Abstract][Full Text] [Related]
19. Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan.
Tanaka T; Shimada K; Yamamoto K; Hirooka Y; Niwa Y; Sugiura I; Kitamura K; Kosugi H; Kinoshita T; Goto H; Nakamura S
Ann Hematol; 2012 Mar; 91(3):383-90. PubMed ID: 21822617
[TBL] [Abstract][Full Text] [Related]
20. Influence of Rituximab on Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma and Role of Prophylaxis--A Systematic Review of Prospective Studies.
Ghose A; Elias HK; Guha G; Yellu M; Kundu R; Latif T
Clin Lymphoma Myeloma Leuk; 2015 Aug; 15(8):451-7. PubMed ID: 25816933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
